Ana Bosch

List of Publications by Year
in descending order

20 papers	1,604 citations	623734 14 h-index	794594 19 g-index
21 all docs	21 docs citations	21 times ranked	3360 citing authors

#	Article	IF	Citations
1	Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews, 2012, 38, 698-707.	7.7	466
2	Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews, 2010, 36, 206-215.	7.7	228
3	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	30.7	218
4	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Science Signaling, 2014, 7, ra29.	3.6	123
5	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. Clinical Cancer Research, 2014, 20, 1935-1945.	7.0	121
6	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
7	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Reports, 2019, 27, 3573-3586.e7.	6.4	66
8	High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer. Oncotarget, 2016, 7, 59640-59651.	1.8	65
9	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747.	12.8	53
10	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature Communications, 2021, 12, 5112.	12.8	38
11	Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. Molecular Cell, 2021, 81, 1453-1468.e12.	9.7	31
12	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. JAMA Oncology, 2021, 7, 1360.	7.1	30
13	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5557-5565.	7.0	26
14	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Research, 2021, 23, 26.	5.0	19
15	Mechanisms of resistance to hormonal treatment in breast cancer. Clinical and Translational Oncology, 2010, 12, 246-252.	2.4	13
16	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular and Cellular Oncology, 2014, 1, e963447.	0.7	9
17	Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study. Carcinogenesis, 2021, 42, 1314-1325.	2.8	8
18	The Strategy of PIKing a Target: What Is AKTually Most Effective?. Clinical Cancer Research, 2018, 24, 2029-2031.	7.0	6

#	Article	IF	Citations
19	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. Journal of Clinical Oncology, 2012, 30, 1074-1074.	1.6	0
20	Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.. Journal of Clinical Oncology, 2022, 40, e12598-e12598.	1.6	0